James Oliviero
Vermogen: 2 M $ op 30-06-2026
Vermogen: 2 M $ op 30-06-2026
James F.
Oliviero is an Independent Director at Nuvectis Pharma, Inc. since 2021.
Formerly, Mr. Oliviero was President, Chief Executive Officer & Director at Checkpoint Therapeutics, Inc. from 2018 to 2025.
Mr. Oliviero was Finance Director at ACCESS Oncology, Inc. from 1999 to 2003.
Mr. Oliviero was Chief Financial Officer & Treasurer at Keryx Biopharmaceuticals, Inc. in 2015.
Mr. Oliviero completed undergraduate studies at Goizueta Business School-Emory.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 11-06-2026 | 122.828 ( 0,46% ) | 2 M $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| NUVECTIS PHARMA, INC. | Directeur/Bestuurslid | 01-07-2021 |
| Bedrijven | Functie | Einde |
|---|---|---|
| CHECKPOINT THERAPEUTICS, INC. | Algemeen Directeur | 30-05-2025 |
| KERYX BIOPHARMACEUTICALS | Financieel Directeur/CFO | 01-09-2015 |
ACCESS Oncology, Inc.
ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Develops pharmaceutical drugs | Financieel Directeur/CFO | 01-05-2003 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on therapies for patients with renal disease | Health Technology |
ACCESS Oncology, Inc.
ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Develops pharmaceutical drugs | Health Technology |
Goizueta Business School-Emory
Goizueta Business School-Emory Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Checkpoint Therapeutics, Inc.
Checkpoint Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops medicines for treatment of cancer | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau